• 1
    Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 104754.
  • 2
    Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 5948.
  • 3
    Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 2807.
  • 4
    Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 17988.
  • 5
    Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van Den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 9838.
  • 6
    Di Michele D. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 56873.
  • 7
    Smith OP. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 1): 225.
  • 8
    Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 88390.
  • 9
    Hedner U. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 2: 1129.
  • 10
    Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 7738.
  • 11
    Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Blood Coagul Fibrinolysis 2000; 11: 23942.
  • 12
    Khoriaty R, Taher A, Inati A, Lee C. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol 2005; 27: 3203.
  • 13
    Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 43340.
  • 14
    Manco-Johnson M. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor viii deficiency. Blood 2005; 16 (Abstract 8).
  • 15
    Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003; 9 (Suppl. 1) : 3842.
  • 16
    Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy–global progress towards optimal care. Haemophilia 2006; 12: 7581.
  • 17
    Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 51722.
  • 18
    Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 11267.
  • 19
    Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 2037.
  • 20
    Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 63848.
  • 21
    Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 2618.
  • 22
    Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 64555.
  • 23
    Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 2006; 4: 2498500.
  • 24
    Almus FE, Rao LV, Fleck RA, Rapaport SI. Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990; 76: 35460.
  • 25
    Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor VIIa. Blood 2003; 102: 170815.
  • 26
    Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res 2004; 94: 103240.
  • 27
    Bokarewa MI, Morrissey J, Tarkowski A. Intra-articular tissue factor/factor VII complex induces chronic arthritis. Inflamm Res 2002; 51: 4717.
  • 28
    Bokarewa MI, Morrissey JH, Tarkowski A. Tissue factor as a proinflammatory agent. Arthritis Res 2002; 4: 1905.
  • 29
    Busso N, Morard C, Salvi R, Peclat V, So A. Role of the tissue factor pathway in synovial inflammation. Arthritis Rheum 2003; 48: 6519.
  • 30
    So AK, Varisco PA, Kemkes-Matthes B et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 25105.
  • 31
    Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006; 43: S1822.
  • 32
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilisation of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Thromb Haemost 1997; 77: 11139.